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Abstract
Angiotensin-converting enzyme inhibitors (ACEIs) are among the most widely prescribed antihypertensive
medications. They are indicated in the management of multiple chronic conditions including hypertension,
diabetes mellitus and heart failure. ACEIs prevent angiotensin II (Ang II) production and bradykinin
catabolism leading to vasodilation and reduction of arterial blood pressure. Recently, the role of the reninangiotensin system (RAS) inhibitors has become the subject of scrutiny in the treatment of cancer metastasis.
The administration of ACEIs, however, has been described to be accompanying with carcinogenic effects.

Introduction
The
angiotensin-converting
enzymes
(ACEs) are active components in reninangiotensin-aldosterone system (Figure 1).
Renin-angiotensin-aldosterone system plays
a major role in the regulation of extracellular
volume and arterial vasoconstriction.
ACE is mainly produced in the lungs by
pulmonary endothelial cells and converts
the angiotensin I hormone to the active
vasoconstrictor, angiotensin II (1). Along
with calcium antagonists (32.2%), ACEIs are
among the most widely prescribed (41%)
antihypertensive medications (2). ACEIs are
widely available and can be administered
in compound with other anti-hypertensive
drugs (3).
Although short-term administration of
ACEIs seems to be safe, their long-term
consumption may induce adverse effects
such as dry cough, hyperkalaemia and
orthostatic hypotension. Furthermore, some
recent studies have declared that ACEIs may
enhance the risk of cancer. For example, in a
cohort study on 992 061 patients, treatment
with ACEIs was shown to be associated
with an increased risk of lung cancer (4). In
fact, lung cancer still is the most common

Key point
Angiotensin-converting
enzyme
inhibitors
prevent the separation of bradykinin and therefore
strengthen the circulating levels of bradykinin
which may participate in tumorigenesis.

neoplasm worldwide with more than 2
million incidences in 2018 alone (11.6% of
all cases) (5).
Despite findings from observational
studies, the carcinogenic effect of ACEIs
have not been yet adequately addressed in the
literature. It must be pointed out, however,
the controversies between results of various
studies may be due to different clinical
conditions or co-prescribed medications.
In addition to activating angiotensin I, ACE
also metabolizes bradykinin, a circulating
peptide released from the cleavage of highmolecular-weight kininogen (HMWK)
(6). Along with histamine, bradykinin
also has a role as a vasoactive substance
in inflammatory processes. Bradykinin
plays a vital role in the pathophysiology of
inherited C1-esterase inhibitor deficiency.
The administration of ACEIs may increase
the level of bradykinin in the lungs which
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Figure 1. The overview of the renin-angiotensin system and angiotensin II receptors.

subsequently can stimulate the growth of lung cancer
cells (4). Bradykinin has also been reported to induce
the release of vascular endothelial growth factor (VEGF)
which promotes angiogenesis (7). Moreover, bradykinin
can augment the lung cancer progression by regulating
blood vessel permeability and promoting tumour invasion
and metastasis (8). Additionally, the administration of
ACEIs has been associated with tumour proliferation
and angiogenesis through overproduction of substance
P which is expressed in lung cancer tissues (9). Finally,
a well-documented common side-effect of ACEIs is dry
and persistent coughing that is supposed to be the result
of ACEIs impacts on the metabolism of bradykinin and
substance P (10). However, a recent study showed no
significant differences in the levels of bradykinin and
substance P in the lungs before and after administration
of ACEIs and angiotensin receptor blockers (11).
Accordingly, the aim of this review was to discuss the
current evidences regarding the limitations and outcomes
of ACEIs in the treatment of hypertension.

renin-angiotensin-aldosterone system. ACEIs hinder the
production of Ang II. Ang II mediates its actions through
both type 1 (i.e. AT1) including vasoconstriction, cell
growth, aldosterone release, renal sodium resorption and
sympathetic activation and type 2 (i.e. AT2) mediates
vasodilation, and inhibition of cell growth (Figure 1).
The major limitation of ACEIs is the failure to effectively
prevent Ang II production probably due to persistent
low-level production of this vasoactive agent through
ACE-independent pathways. Through the activation of
AT2 receptors, Ang II may promote vasodilatory and
anti-proliferative activities. In fact, ACEIs prevent the
separation of bradykinin and therefore strengthen the
circulating levels of bradykinin which may participate in
tumorigenesis (12). Bradykinin has also been reported
to play a significant role in mediating vasodilation (13).
Moreover, bradykinin increases the synthesis of potent
vasoactive agents such as nitric oxide and prostaglandins
(14). Through these effects, ACEIs are believed to play a
major role in cancer development (15).

Materials and Methods
For this mini-review, we used a variety of sources
including PubMed, Web of Science, Embase,
EBSCO, Google Scholar and Scopus. The search
was conducted by using combinations of the
following key words and or their equivalents;
antihypertensive medications, cancer, renin‐angiotensin
system inhibitors, renin-angiotensin system and lung
cancer.

Comparison of outcomes
Individuals without cardiac insufficiency
In individuals with high blood pressure, treatment with
ACEIs has significantly reduced all-cause mortality (16).
Because of the high prevalence of hypertension, using
ACEIs to manage this condition may save many lives
(16). In a large meta-analysis of randomized placebocontrolled trials, on patients with hypertension and no
heart failure, it was indicated that the efficiency and safety
of ARBs (angiotensin-receptor blockers) and ACEIs were
comparable (17).
Likewise, in a meta-analysis on patients with high risk

Mechanism of action
The process of ACEIs action is interrelated with the
2
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of cardiovascular disease (CVD) (without heart failure),
the mortality rate was compared between individuals
treated with either ARBs or ACEIs (18). The study showed
no substantial evidence on the superior impact of ACEIs
in preventing CVD related mortality in comparison to
ARBs. Therefore, evidence indicates similar efficacy of
ARBs and ACEIs in preventing mortality in patients with
hypertension and high risk of CV events.
Patients with coronary artery disease
The efficiency of ACEIs in patients with coronary artery
disease is yet to be verified in future researches (19). Only
indirect comparisons have been conducted on the core of
the myocardial infarction paradox. Although it has been
proposed that ARBs may be safer than ACEIs, this theory
suffers from the lack of data from direct head-to-head
trials (20).
Patients with heart failure
ACEIs have been confronted with placebo in numerous
clinical trials on individuals with heart failure (2). A
meta-analysis by Burnett et al demonstrated that ACEIs
administration in individuals with chronic heart failure
reduced the mortality rate compared to placebo (21).
Furthermore, the “Cooperative North Scandinavian
Enalapril Survival” study reported 31% decrease in
1-year mortality rate in individuals with serious cardiac
insufficiency remedied with ACEIs when compared to
placebo (22). Packer et al (23) have detected the efficacy
of ACEIs to their impacts on endogenous compensatory
vasoactive substances that are recruited by ACEIs but not
by ARBs. This fact may pave the route for wider application
of the RAS inhibitors as potential endogenous vasoactive
peptides in patients with heart failure.
Patients with chronic kidney disease
In a multi-center, randomized, double-blind, controlled
clinical trial on 25 620 participants at high risk of vascular
events, ACEIs showed similar effects compared with ARBs
in terms of primary renal outcomes including dialysis,
doubling of serum creatinine and mortality (24).
Diabetic patients
Barnett et al, conducted a double-blind, randomized
clinical trial, multicenter study on 250 subjects with
type 2 diabetes. They found, the effects of ACEIs on the
secondary outcomes were not significant following five
years of treatment (25). Accordingly, in a meta-analysis of
71 clinical trials on diabetic patients, no notable difference
was detected in the all-cause mortality rate between the
users of either ACEIs or ARBs (26).
Patients with cerebrovascular disease
Most head-to-head analysis revealed no variation in the
stroke rates comparing patients with cerebrovascular
disease treated with either ARBs or ACEIs (27). In a recent

meta-analysis on patients with systolic hypertension,
ACEIs reduced cardiovascular outcomes compared with
placebo; nevertheless, they were unsuccessful to inhibit
stroke (28).
Adverse events
ACEIs have been associated with dry and irritating
coughing as their most common adverse effect (29).
This event has encouraged many physicians to no longer
prescribe ACEIs. In addition, Banerji et al (30) reported
that among 134,945 patients administrated with ACEIs,
0.7 % (n=888) developed angioedema following five
years. Compared with ARBs, Hicks et al in a populationbased cohort study revealed an increased risk of lung
cancer associated with ACEIs with the highest risk being
observed at more than ten years after ACEIs utilization
(4). In the recent study, authors reported that ACEIs were
accompanied with 14% greater overall risk of lung cancer
(hazard ratio=1.14, 95% confidence interval; 1.01 to 1.29)
(4). Although the 14% increase in the risk of lung cancer
may not turn to a large uncontrolled risk, the findings are
significant given the substantial usage of ACEIs worldwide.
Anti-cancer impact of ACEIs
By the way, recent evidence has detected the role of reninangiotensin system (RAS) in tumoral alteration and its
progression (31). Consequently, the probable anti-cancer
mechanisms of RAS blockers consist of modulating
nuclear factor (NF)-κB, prevent matrix metalloproteinases
(MMP-9 and MMP-2) production, a suppressing effect on
VEGF, and diminish the production of hypoxia-inducible
factor 1 (HIF-1). Accordingly, probable anti-cancer
mechanisms of RAS blockers may be due to stimulation of
angiostatin (only captopril), and diminish the aggregation
of tumour-related macrophages by MCP-1 decrement,
finally directing to reduced micro-vessel compactness and
lessening of the tumour inflammatory location, and also
tumour development reversion. These important findings
should keep in mind when we talk about the impact of
ACEIs on lung cancer (31-34). In fact, the study by Hicks
et al (4), needs further investigation by more multi-centric,
multi-ethnic studies.
Conclusion
The clinical efficiency of ACEIs is a controversial topic in
the scientific community with some studies have suggested
increased, decreased, or unchanged risk of cancer in
patients treated with ACEIs (32-35). Meta-analyses which
are based on registered data of big populations may be
beneficial to extrapolate long-term effects of ACEIs;
however, these may not be indicated to predict outcomes in
small clinical trials. Nevertheless, in an individual patient,
concerns about the long-term risk of lung cancer should
be balanced against gains in life expectancy associated
with the administration of ACEIs. Further comprehensive
studies are needed to provide more valid scientific evidence
Immunopathologia Persa Volume 5, Issue 2, 2019
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on the long-term safety of ACEIs.
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